We selected BNC105, a microtubule-binding drug used as a vascular targeting agent for cancer, and Palbociclib, a CDK4/6 inhibitor approved for cancer therapy, and compared the cell-killing efficiency of these substances to that of Bortezomib, either alone or in combination. The gene discussed is CDK4; the disease is cancer.